Elagolix
Oriahnn, Orilissa (elagolix) is a small molecule pharmaceutical. Elagolix was first approved as Orilissa on 2018-07-23. It is used to treat abdominal pain in the USA. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Orilissa
CombinationsOriahnn
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| abdominal pain | EFO_0003766 | D015746 | R10.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ELAGOLIX SODIUM, ORILISSA, ABBVIE | |||
| 2023-07-23 | NCE | ||
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE / ELAGOLIX SODIUM, ORIAHNN (COPACKAGED), ABBVIE | |||
| 2023-07-23 | NCE | ||
| 2023-05-29 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Elagolix Sodium, Orilissa, Abbvie | |||
| 11542239 | 2039-07-23 | DS, DP | |
| 10537572 | 2036-09-01 | U-2735 | |
| 10682351 | 2036-09-01 | U-2850 | |
| 11344551 | 2034-03-14 | U-3388, U-3389 | |
| 7056927 | 2024-09-10 | DS, DP | |
| 7176211 | 2024-07-06 | U-2360 | |
| 7419983 | 2024-07-06 | DS, DP | U-2360 |
| Elagolix Sodium,Estradiol,Norethindrone Acetate / Elagolix Sodium, Oriahnn (Copackaged), Abbvie | |||
| 10881659 | 2034-03-14 | U-2842 | |
| 11045470 | 2034-03-14 | U-2842 | |
| 11459305 | 2028-11-07 | DP | U-2842 |
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leiomyoma | D007889 | — | D25 | — | 2 | 4 | 1 | 4 | 11 |
| Myofibroma | D047708 | — | — | — | 2 | 4 | 1 | 3 | 10 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | 2 | 4 | 1 | 2 | 9 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 2 | 4 | 1 | 1 | 8 |
| Anovulation | D000858 | — | — | — | — | — | 1 | — | 1 |
| Adenoma | D000236 | — | — | — | — | — | 1 | — | 1 |
| Adrenocortical adenoma | D018246 | — | — | — | — | — | 1 | — | 1 |
| Cushing syndrome | D003480 | EFO_0003099 | E24 | — | — | — | 1 | — | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 1 | — | 1 |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometriosis | D004715 | EFO_0001065 | N80 | 2 | 7 | 11 | — | 3 | 23 |
| Infertility | D007246 | EFO_0000545 | — | 1 | 1 | 2 | — | — | 4 |
| Dysmenorrhea | D004412 | — | N94.6 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine hemorrhage | D014592 | — | — | — | 2 | — | — | — | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Elagolix |
| INN | elagolix |
| Description | Elagolix is an organooxygen compound and an organonitrogen compound. It is functionally related to a gamma-amino acid. |
| Classification | Small molecule |
| Drug class | gonadotropin releasing hormone (GnRH) receptor antagonists (nonpeptide) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F |
Identifiers
| PDB | — |
| CAS-ID | 834153-87-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1208155 |
| ChEBI ID | — |
| PubChem CID | 11250647 |
| DrugBank | DB11979 |
| UNII ID | 5B2546MB5Z (ChemIDplus, GSRS) |
Target
Agency Approved
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Oriahnn – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 451 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oriahnn
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,126 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use